文献速递血栓与止血白血病

免疫治疗为基础的全新辅助治疗用于错配修复完整或微卫星稳定局部晚期直肠癌的随机II期试验(TORCH)

Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
PubMed 文献 · J Clin Oncol · 2024-07-01

这项前瞻性、多中心、随机、开放标签、优选者设计的II期试验纳入130例临床T3-4和/或N+直肠腺癌患者,121例pMMR/MSS患者可评估(A组62例,B组59例)。中位随访19个月,A组完全缓解率56.5%,B组54.2%,两组均满足预设统计假设(P<.001),病理完全缓解率均为50%。

要点

  • A组完全缓解率56.5%,B组54.2%,均满足预设假设(P<.001)。
  • 两组病理完全缓解率均为50%,每组各有15例患者接受观察等待策略。
  • A组再分期时临床完全缓解率43.5% vs B组35.6%,3-4级血小板减少发生率24.2% vs 33.9%。

核心结论

  • 与历史基准相比,免疫化疗联合全新辅助治疗显著提高pMMR/MSS局部晚期直肠癌的完全缓解率,毒性可接受。
  • 作者选择先进行短程放疗后免疫化疗的方案用于未来确证性研究。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签、优选者设计的II期试验。
  • 纳入临床T3-4和/或N+直肠腺癌患者,随机分入A组或B组。
  • A组:短程放疗后接受6周期卡培他滨、奥沙利铂和特瑞普利单抗巩固免疫化疗。
  • B组:2周期诱导免疫化疗后接受短程放疗,再接受剩余4剂免疫化疗。
  • 根据肿瘤反应选择全直肠系膜切除术或观察等待策略。

主要发现

  • 中位随访19个月,A组完全缓解率56.5%,B组54.2%。
  • 两组均满足预设统计假设(P<.001)。
  • 两组病理完全缓解率均为50%。
  • 每组各有15例患者接受观察等待策略并保持无病。
  • 最常见的3-4级毒性为血小板减少和中性粒细胞减少。

关键数值与推荐

  • 历史对照常规全新辅助治疗后完全缓解率为25%,本研究假设免疫化疗联合全新辅助治疗可提高至40%。
  • A组完全缓解率56.5%,B组54.2%,均满足预设假设(P<.001)。
  • A组病理完全缓解率50%,B组病理完全缓解率50%。
  • A组再分期时临床完全缓解率43.5% vs B组35.6%。
  • A组新辅助治疗期间3-4级血小板减少发生率24.2% vs B组33.9%。

临床怎么用

  • 作者选择先进行短程放疗后免疫化疗的方案用于未来确证性研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSETo assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC).PATIENTS AND METHODSWe conducted a prospective, multicenter, randomized, open-label, phase II trial using a pick-the-winner design. Eligible patients with clinical T3-4 and/or N+ rectal adenocarcinoma were randomly assigned to group A for short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab or to group B for two cycles of induction immunochemotherapy followed by SCRT and the rest four doses. Either total mesorectal excision or WW was applied on the basis of tumor response. The primary end point was CR which included pathological CR (pCR) after surgery and clinical CR (cCR) if WW was applicable, with hypothesis of an increased CR of 40% after iTNT compared with historical data of 25% after conventional TNT.RESULTSOf the 130 patients enrolled, 121 pMMR/MSS patients were evaluable (62 in group A and 59 in group B). At a median follow-up of 19 months, CR was achieved at 56.5% in group A and 54.2% in group B. Both groups fulfilled the predefined statistical hypothesis (P < .001). Both groups reported a pCR rate of 50%. Respectively, 15 patients in each group underwent WW and remained disease free. The most frequent grade 3 to 4 toxicities were thrombocytopenia and neutropenia. Patients in group A had higher rate of cCR (43.5% v 35.6%) at restaging and lower rate of grade 3 to 4 thrombocytopenia (24.2% v 33.9%) during neoadjuvant treatment.CONCLUSIONThe iTNT regimens remarkably improved CR rates in pMMR/MSS LARC compared with historical benchmark with acceptable toxicity. Up-front SCRT followed by immunochemotherapy was selected for future definitive study.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Xia F, Wang Y, Wang H, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). J Clin Oncol. 2024. PMID: 38950321. doi:10.1200/JCO.23.02261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。